期刊文献+

左旋多巴药物基因组学的研究进展 被引量:4

Research advances in pharmacogenomics of levodopa
下载PDF
导出
摘要 左旋多巴被认为是治疗帕金森病的金标准,本文综述了多个相关基因的遗传多态性对左旋多巴药代动力学、药效学及不良反应的影响,以期为指导左旋多巴的临床个体化用药提供基础。 Levodopa is considered to be the gold standard treatment for Parkinson's disease. This review aimed to summarize the influence of genetic polymorphisms on levodopa pharmacoki- netics, pharmacodynamics and adverse reac-tions. In order to provide the basis for guide the clinical individualized medication of levodopa .
作者 宁巍 刘洁
出处 《中国临床药理学与治疗学》 CAS CSCD 2013年第4期455-460,共6页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 国家自然科学基金项目(30600774 81070902) 教育部新世纪优秀人才支持计划(NCET-08-0567) 中国博士后科学基金特别资助(201104515) 中国博士后科学基金面上项目(2012M510138)资助
关键词 左旋多巴 基因多态性 帕金森病 Levodopa Genetic polymor- phisms Parkinson's disease
  • 相关文献

参考文献38

  • 1Ahlskog JE,Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as esti-mated from the cumulative literature [J],Mov Dis-ord,2001,16(3); 448-458.
  • 2沈杰,谢海棠,刘昭前.遗传药理学与高血压药物治疗进展[J].中国临床药理学与治疗学,2010,15(6):705-714. 被引量:8
  • 3LottaT,Vidgren J,Tilgmann C.et al. Kinetics ofhuman soluble and membrane-bound catechol O-methyltransferase ; a revised mechanism and de-scription of the thermolabile variant of the enzyme[J].Biochemistry,1995,34(13):4202-4210.
  • 4戴洪,袁凤仪,邵明,王义军,陈亚东.帕金森病患者儿茶酚氧位甲基转移酶基因多态性与左旋多巴诱导的运动障碍的关系[J].中华老年心脑血管病杂志,2005,7(3):178-180. 被引量:3
  • 5de Lau LM,Verbaan D,Marinus J et al. Catechol-O-methyltransferase Vail 58Met and the risk of dys-kinesias in Parkinson's disease [J].Mov Disord,2012,27(1):132-135.
  • 6Lee MS,Lyoo CH,Ulmanen I,et al. Genotypes ofcatechol-O-methyltransferase and response to levo-dopa treatment in patients with Parkinson's disease[J].Neurosci Lett,2001,298(2) :131-134.
  • 7Watanabe M,Harada S,Nakamura T,et al. As-sociation between catechol-O-methyltransferase genepolymorphisms and wearing-off and dyskinesia inParkinson's disease [J].Neuropsychobiology,2003,48(4) :190-193.
  • 8Contin M,Martinelli P,Mochi M ,et al. Geneticpolymorphism of catechol-O-methyltransferase andlevodopa pharmacokinetic-pharmacodynamic patternin patients with Parkinson's disease [J].Mov Dis-ord,2005,20(6):734-739.
  • 9Lin CH,Wang CL,Huang PF,et al. Genetic poly-morphism of catechol O-methyltransferase and phar-macokinetics of levodopa in healthy Chinese subjects[J].Methods Find Exp Clin Pharmacol,2009,31(6):389-395.
  • 10CorvolJC,Bonnet C,Charbonnier-Beaupel F,et al.The COMT Vall58Met polymorphism affects theresponse to entacapone in Parkinson's disease:arandomized crossover clinical trial [J].Ann Neurol,2011,69(1):111-118.

二级参考文献6

共引文献9

同被引文献116

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部